ANI Pharmaceuticals Announces the Launch of Carbamazepine Extended-Release Capsules
Rhea-AI Summary
ANI Pharmaceuticals (Nasdaq: ANIP) launched Carbamazepine Extended-Release Capsules in 100 mg, 200 mg and 300 mg strengths on April 13, 2026.
The product is a generic version of the reference listed drug Carbatrol. ANI said the launch targets a limited competition segment and cited U.S. annual sales of approximately $65 million based on February 2026 MAT IQVIA data.
Positive
- Launch of Carbamazepine ER in 100/200/300 mg expands generics portfolio
- Product is a generic of Carbatrol, enabling substitution opportunities
- Addresses a U.S. market with estimated $65 million annual sales (Feb 2026 MAT IQVIA)
Negative
- None.
News Market Reaction – ANIP
In the Apr 13 session, ANIP declined 0.06%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 08 | FDA approval launch | Positive | -0.6% | FDA approval and launch of Isosorbide Mononitrate generic tablets. |
| Apr 07 | Clinical data update | Neutral | +2.9% | Publication of Phase 4 ILUVIEN NEW DAY trial safety and efficacy data. |
| Feb 27 | Earnings results | Positive | -4.2% | Record Q4 and 2025 results with strong revenue and EBITDA growth. |
| Feb 24 | Investor conferences | Neutral | +2.1% | Announcement of multiple March investor conference presentations. |
| Feb 13 | Earnings call notice | Neutral | +0.9% | Scheduling details for Q4 and full-year 2025 earnings release and call. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive fundamental news (earnings, FDA approval) often saw negative price reactions, suggesting a pattern of selling into good news.
In the last six months, ANIP reported record Q4 and full-year 2025 results with net revenue of $247.1M for Q4 and $883.4M for 2025, plus strong Cortrophin Gel growth, yet the stock fell 4.21% on that earnings release. An FDA approval and launch of Isosorbide Mononitrate Tablets on Apr 8, 2026 also saw a modest -0.58% move. Clinical and conference updates in February–April produced small positive reactions, showing a mixed but often contrarian response to good news.
Key Terms
reference listed drug regulatory
extended-release medical
moving annual total financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
PRINCETON, N.J., April 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Carbamazepine Extended-Release Capsules, 100 mg, 200 mg and 300 mg. ANI’s Carbamazepine Extended-Release Capsules are the generic version of the reference listed drug (RLD) Carbatrol®.
"Continuing to strengthen our Generics portfolio through strategic product launches remains a key priority for us,” stated Nikhil Lalwani, President and Chief Executive Officer of ANI. “The launch of Carbamazepine Extended-Release Capsules, another limited competition product, highlights our continued commitment to improving patient access to essential medicines while maintaining the highest standards of quality and compliance.”
U.S. annual sales for Carbamazepine Extended-Release Capsules total approximately
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives” by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit www.anipharmaceuticals.com.
Forward-Looking Statements
To the extent any statements made in this release relate to information that is not historical, these are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding the Company’s strategy; its plans with respect to the commercialization and potential sales of the Company’s products, including the launch of Carbamazepine Extended-Release Capsules; its efforts to bring limited-competition products to market and ensure that is high-quality products are readily accessible to its customers and patients in need; expansion plans for the Company’s Rare Disease, Generics and Brands businesses; and other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “plans,” “potential,” “future,” “believes,” “intends,” “continue,” the negatives thereof, or other words of similar meaning, derivations of such words and the use of future dates.
Uncertainties and risks may cause the Company’s actual results to be materially different than those expressed in or implied by such forward-looking statements. Uncertainties and risks include, but are not limited to: the ability of the Company’s approved products to achieve commercialization at levels of market acceptance that will allow the Company to maintain profitability; delays and disruptions in the production of the Company’s approved products; delays or failure to obtain or maintain approvals by the FDA of the Company’s products; changes in policy or actions that may be taken by the FDA, United States Drug Enforcement Administration and other regulatory agencies; risks that the Company may face with respect to importing raw materials and delays in delivery of raw materials and other ingredients and supplies necessary for the manufacture of the Company’s products from both domestic and overseas sources due to supply chain disruptions or for any other reason; the ability of the Company’s manufacturing partners to meet its product demands and timelines; the level of competition the Company faces and the legal, regulatory and/or legislative strategies employed by its competitors to prevent or delay competition from generic alternatives to branded products; the impact of legislative or regulatory reform on the pricing for pharmaceutical products; the Company’s ability, and that of its suppliers, development partners, and manufacturing partners, to comply with laws, regulations and standards that govern or affect the pharmaceutical and biotechnology industries; and general business and economic conditions, such as inflationary pressures and geopolitical conditions.
More detailed information on these and additional factors that could affect the Company’s actual results are described in the Company’s filings with the Securities and Exchange Commission (SEC), including its most recent annual report on Form 10-K and quarterly reports on Form 10-Q, and other periodic reports, as well as other filings with the SEC. All forward-looking statements in this news release speak only as of the date of this news release and are based on the Company’s current beliefs, assumptions, and expectations. The Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Investor Relations:
Courtney Mogerley, Argot Partners
T: 646-368-8014
E: ani@argotpartners.com
Source: ANI Pharmaceuticals, Inc.
